ArticleJournal of dental sciences2026
Synergistic effects of biodegradable magnesium alloy and erythromycin on osteogenic activity.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Biodegradable magnesium (Mg)-based alloys are emerging as promising alternatives to non-resorbable titanium for bone regeneration because of their favorable mechanical properties and biodegradability. However, the interaction between Mg alloys and immunomodulatory agents in promoting osteogenesis remains poorly understood. This study aimed to evaluate the osteogenic effects of an Mg alloy on pre-osteoblasts and to investigate whether erythromycin enhances Mg-induced osteogenic differentiation through regulation of developmental endothelial locus-1 (DEL-1). Materials and methods: WE43 Mg alloy disks were immersed in culture medium to produce Mg alloy-conditioned medium at concentrations of 25%, 50%, 75%, and 100%. MC3T3-E1 cells were treated with conditioned medium alone or combined with erythromycin (20 μg/mL). Cell viability was assessed using the MTT assay. Osteogenic differentiation was evaluated by Alizarin Red S staining (ARS), quantitative PCR analysis of osteogenic markers ( Results: WE43 Mg alloy showed no cytotoxic effects on MC3T3-E1 cells. Treatment with Mg alloy-conditioned medium significantly enhanced osteogenic differentiation and extracellular matrix mineralization. The strongest osteogenic response was observed in cells receiving combined WE43 Mg alloy and erythromycin treatment. DEL-1 expression was significantly upregulated at both mRNA and protein levels in Mg alloy-treated groups, accompanied by increased expression of osteogenic markers. These effects were further amplified by erythromycin supplementation. Conclusion: WE43 Mg alloy promotes osteogenic differentiation of MC3T3-E1 cells, and erythromycin synergistically enhances this effect, potentially via DEL-1 upregulation. These findings support the combined use of immunomodulatory agents and Mg-based biomaterials in regenerative dentistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.